Compare Salesforce Inc (CRM) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Smith & Nephew plc — how do they compare? Salesforce Inc trades at $191.86 (market cap $161.73B), while Smith & Nephew plc trades at $29.78 (market cap $12.54B). The key difference: Salesforce Inc is far larger — about 12.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| CRM | SNN | |
|---|---|---|
Market Cap | $161.73B | $12.54B |
Sector | Technology | Health |
52-Week High | $266.23 | $38.70 |
52-Week Low | $150.12 | $28.73 |
Enterprise Value | $191.77B | $15.57B |
Dividend Yield | 0.89% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $192.28, down 2.65% today amid a broader tech sell-off, but maintains strong fundamentals with consistent earnings beats, robust profitability margins, and solid cash flow growth. The stock exhibits a bullish technical trend with key support at $193, while analyst consensus remains overwhelmingly positive with a $230.83 price target. Recent news highlights AI-driven growth potential but also sector-wide volatility concerns.
Outlook is favorable given CRM's rule of 44 performance, AI monetization momentum, and discounted valuation, though risks include competitive pressures, macroeconomic headwinds, and elevated RSI levels suggesting near-term overbought conditions. The company's double-digit revenue growth and expanding margins support long-term upside if execution continues.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
